QC
GOSS icon

Quantessence Capital’s Gossamer Bio GOSS Stock Holding History

Quantessence Capital’s Portfolio GOSS Stock Details GOSS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-118,349
Closed -$130K – 292
2025
Q1 		$130K Buy
+118,349
New +$137K 0.03% 297

Other funds holding GOSS

OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Quantessence Capital's GOSS Position: Q2 2025 in Review

Quantessence Capital sold out of Gossamer Bio (GOSS) in Q2 2025, closing a stake of 118,349 shares — an estimated $130K sold.

Quantessence Capital first reported a position in GOSS in Q1 2025 and held it in 1 quarter. The position peaked at $130K in Q1 2025. 123 funds tracked by Wall St. Rank hold GOSS as of Q2 2025.

  • Quantessence Capital reported no remaining Gossamer Bio position as of Q2 2025 after selling out during the quarter.
  • Quantessence Capital sold 118,349 Gossamer Bio shares in Q2 2025, an estimated $130K.
  • Quantessence Capital first reported a position in Gossamer Bio in Q1 2025 and held it in 1 quarter.
  • Quantessence Capital's Gossamer Bio position peaked at $130K in Q1 2025.
  • 123 funds tracked by Wall St. Rank held Gossamer Bio as of Q2 2025.

Based on Quantessence Capital's 13F filing for Q2 2025, filed 14 Aug 2025.